JPJhon Prieto

Jhon Prieto

*This is an algorithmically generated author record based on publicly available information.

Jhon Prieto has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aflatoxin B1 Exposure and Hepatocellular Carcinoma in South America: A Multinational Cross-Sectional Analysis

    by Ramón Asis, Marina L. Fernandez, Gustavo Bonacci, Jose Debes, Jhon Prieto, Andre Boonstra, Domingo C. Balderramo, Pablo A. Romagnoli

    Aflatoxin B1 (AFB1), a dietary mycotoxin classified as a Group 1 carcinogen and a risk factor for hepatocellular carcinoma (HCC), has seen limited biomarker-based evidence linking it to HCC in South America despite favorable regional contamination conditions. Utilizing a newly validated isotope-dilution HPLC–MS/MS method to quantify AFB1-Lysine (AFB1-Lys) adducts, we conducted a cross-sectional study involving 92 HCC patients and 70 healthy controls across six South American nations. The primary case–control analysis, focusing on 64 HCC patients and 70 controls from Argentina and Colombia, revealed that AFB1-Lys concentrations and positivity rates were significantly higher in HCC cases compared to controls (7.16 vs. 0.89 pg/mg albumin; 43% vs. 10%). Multivariable logistic regression demonstrated that detectable AFB1-Lys was significantly and independently associated with HCC (adjusted OR = 3.72), with associations most pronounced, though based on small subgroups, in viral hepatitis-related and cryptogenic HCC. Furthermore, broader regional analysis indicated higher AFB1-Lys positivity rates in HBV-positive patients than in HCV-positive or non-viral HCC cases. Ultimately, chronic dietary aflatoxin exposure shows a consistent, statistically significant association with hepatocarcinogenesis across diverse etiological backgrounds in South America, highlighting an urgent need for integrated regional food safety surveillance and expanded prospective studies.


  • Open Access

    Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe

    by Boris J.B. Beudeker, Siyu Fu, Domingo Balderramo, Angelo Z. Mattos, Enrique Carrera, Javier Diaz, Jhon Prieto, Jesus Banales, Arndt Vogel, Marco Arrese, et al.

    Background: HCC is a major cause of cancer death worldwide. Serum biomarkers such as alpha-fetoprotein (AFP), protein induced by vitamin K absence-II, and the Gender, Age, AFP-L3, AFP, Des-gamma-carboxy prothrombin (GALAD) score have been recommended for HCC surveillance. However, inconsistent recommendations in international guidelines limit their clinical utility. Methods: In this multicenter study, over 2000 patient samples were collected in 6 Latin American and 2 European countries. The performance of the GALAD score was validated in cirrhotic cases, and optimized versions were tested for early-stage HCC and prediagnostic HCC detection. Results: The GALAD score could distinguish between HCC and cirrhosis in Latin American patients with an AUC of 0.76, sensitivity of 70%, and specificity of 83% at the conventional cutoff value of −0.63. In a European cohort, GALAD had an AUC of 0.69, sensitivity of 66%, and specificity of 72%. Optimizing the score in the 2 large multicenter cohorts revealed that AFP-L3 contributed minimally to early-stage HCC detection. Thus, we developed a modified GALAD score without AFP-L3, the ASAP (age, sex, AFP, and protein induced by vitamin K absence-II), which showed promise for early-stage HCC detection upon validation. The ASAP score also identified patients with cirrhosis at high risk for advanced-stage HCC up to 15 months before diagnosis (p < 0.0001) and differentiated HCC from hemangiomas, with a specificity of 100% at 71% sensitivity. Conclusion: Our comprehensive analysis of large sample cohorts validates the GALAD score’s utility in Latin American, Spanish, and Dutch patients for early-stage HCC detection. The optimized GALAD without AFP-L3, the ASAP score, is a good alternative and shows greater promise for HCC prediction.


  • Open Access

    Hígado graso: una epidemia silente

    by Jhon Edison Prieto Ortiz

    El hígado graso o NAFLD afecta aproximadamente al 25% de la población mundial y es una de las primeras causas de consulta en los servicios de hepatología y de especialistas clínicos, por lo cual el objetivo de esta revisión es dar un enfoque actual, que llegue al mayor número de médicos en nuestro país. La entidad se define como la presencia de esteatosis hepática en una prueba de imagen o una biopsia hepática, más la ausencia de causas secundarias. La génesis del hígado graso es el resultado de la interacción de múltiples factores, entre los que predominan los genéticos, el acúmulo de grasas hepáticas, la resistencia a la insulina y la microbiota intestinal, que llevan a un daño hepatocelular a través de la formación de radicales libres de oxígeno y la posterior activación de la fibrogénesis hepática. El tratamiento se basa fundamentalmente en la pérdida de peso con dieta y ejercicio, continuando con medidas farmacológicas, no farmacológicas y procedimientos quirúrgicos.

  • Open Access

    Serum Biomarkers for the Prediction of Hepatocellular Carcinoma

    by José D. Debes, Pablo A. Romagnoli, Jhon Prieto, Marco Arrese, Angelo Z. Mattos, André Boonstra, on behalf of the ESCALON Consortium

    Hepatocellular carcinoma (HCC) is a leading cause of global cancer death. Major etiologies of HCC relate to chronic viral infections as well as metabolic conditions. The survival rate of people with HCC is very low and has been attributed to late diagnosis with limited treatment options. Combining ultrasound and the biomarker alpha-fetoprotein (AFP) is currently one of the most widely used screening combinations for HCC. However, the clinical utility of AFP is controversial, and the frequency and operator-dependence of ultrasound lead to a variable degree of sensitivity and specificity across the globe. In this review, we summarize recent developments in the search for non-invasive serum biomarkers for early detection of HCC to improve prognosis and outcome for patients. We focus on tumor-associated protein markers, immune mediators (cytokines and chemokines), and micro-RNAs in serum or circulating extracellular vesicles and examine their potential for clinical application.